Ridaforolimus Uses, Dosage, Side Effects and more

Attribute	Details
Trade Name	Ridaforolimus
Generic	Ridaforolimus
Ridaforolimus Other Names	Deforolimus, Ridaforolimus
Type
Formula	C53H84NO14P
Weight	Average: 990.222 Monoisotopic: 989.562943387
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.

How Ridaforolimus works

Deforolimus inhibits the mammalian target of rapamycin (mTOR), a serine kinase of the phosphatidylinositol-3-kinase (PI3K) family that regulates protein synthesis, affecting cell growth and proliferation. mTOR is a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways which cancer cells need to proliferate.

Innovators Monograph